Immulina Tm
Post Acute COVID-19 Syndrome
University of Mississippi Medical CenterPhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
31 Active assets in the Post Acute COVID-19 Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Paxlovid Kanecia Obie Zimmerman | Phase 2 | B |
MELATONIN Duke University | Phase 2 | B |
Rapamycin Icahn School of Medicine at Mount Sinai | Phase 3 | B |
IVABRADINE Kanecia Obie Zimmerman | Phase 2 | B |
RITONAVIR Kanecia Obie Zimmerman | Phase 2 | B |
View all 31 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →